Here is the design of a clinical trial:

Official Title: Sensory-Motor and Cardiorespiratory Rehabilitation Associated With Transcranial Laser Therapy in Patients With Central Nervous System Injury

Included conditions:
- Post Stroke
- Post-Traumatic Headache
- Spinal Injuries
- Cerebral Palsy, Spastic
- Surgery
- Sclerosis, Multiple
- Spastic

Study Armgroups:
- {'label': 'Control-Cardiorespiratory Rehabilitation', 'type': 'ACTIVE_COMPARATOR', 'description': 'These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.', 'interventionNames': ['Procedure: Cardiorespiratory Rehabilitation']}
- {'label': 'Transcranial Photobiomodulation Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.', 'interventionNames': ['Procedure: Transcranial Photobiomodulation (Placebo)', 'Procedure: Cardiorespiratory Rehabilitation']}
- {'label': 'Transcranial Photobiomodulation', 'type': 'EXPERIMENTAL', 'description': 'In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.', 'interventionNames': ['Procedure: Transcranial Photobiomodulation', 'Procedure: Cardiorespiratory Rehabilitation']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Transcranial Photobiomodulation', 'description': 'Photobiomodulation Rehabilitation:\n\nDiode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) .', 'armGroupLabels': ['Transcranial Photobiomodulation']}
- {'type': 'PROCEDURE', 'name': 'Transcranial Photobiomodulation (Placebo)', 'description': 'Photobiomodulation Placebo Therapy:\n\nThe same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off.', 'armGroupLabels': ['Transcranial Photobiomodulation Placebo']}
- {'type': 'PROCEDURE', 'name': 'Cardiorespiratory Rehabilitation', 'description': 'Cardiorespiratory Rehabilitation:\n\nAerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.', 'armGroupLabels': ['Control-Cardiorespiratory Rehabilitation', 'Transcranial Photobiomodulation', 'Transcranial Photobiomodulation Placebo']}

Primary Outcomes:
- {'measure': 'Change in Muscular electrical activity (Surface electromyograph).', 'description': 'The surface electrodes will be positioned in the rectus femoris and femoral biceps muscles. The evaluation of the muscles will be realized during the squat movement. 10 seconds of signal collection (in triplicate).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of bipodal balance during the squat movement.', 'description': 'The balance evaluation will be performed during the squat movement on the power platform (Stabilometric analysis in Kgf). 10 seconds of signal collection (in triplicate).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of the heart rate variability to study the responses of the autonomic nervous system', 'description': 'Heart rate variability will be assessed during aerobic training on the treadmill for 40 minutes (5 minutes of initial rest, 30 minutes of exercise and 5 minutes of final rest).', 'timeFrame': 'Baseline (First day of rehabilitation) and after 9 weeks (Last day of rehabilitation).'}
- {'measure': 'Change in Pulmonary function analysis (spirometry): forced vital capacity', 'description': 'Using the spirometry technique, forced vital capacity (measured in liters) will be evaluated. The volunteer will be asked to perform the maximum inspiration and exhale with maximum effort.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in Pulmonary function analysis (spirometry): forced expiratory volume in the first second', 'description': 'Using the spirometry technique, forced expiratory volume in the first second (measured in liters) will be evaluated. The volume of exhaled air in the first second in the forced vital capacity maneuver will be evaluated.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in Pulmonary function analysis (spirometry): Tiffeneau Index', 'description': 'Using the spirometry technique, Tiffeneau Index will be evaluated. The Tiffeneau index is the result of the division of forced expiratory volume in the first second in relation to forced vital capacity.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in Pulmonary function analysis (spirometry): maximum voluntary ventilation', 'description': 'Using the spirometry technique, maximum voluntary ventilation will be evaluated. Maximum voluntary ventilation is the largest volume of air that the individual can mobilize in one minute with maximum voluntary effort. The test gives an overview of the ventilatory function (measured in L / min).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of inspiratory muscle strength', 'description': 'The inspiratory muscle strength will be evaluated by means of the manovacuometer.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Analysis of expiratory muscle strength', 'description': 'The expiratory muscle strength will be evaluated by means of the manovacuometer', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of Peak expiratory flow.', 'description': 'To analyze the velocity of the air out of the lungs.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of the thoracic expandability (axillary level).', 'description': 'In order to analyze the chest expansion at the axillary level, a metric tape placed at the torarico-axillary level will be used, which will measure the inspiratory and expiration mobility values, and will be subtracted (Insp-Exp).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of the thoracic expandability (xiphoid level).', 'description': 'In order to analyze the chest expansion at the xiphoid level, a metric tape will be used, placed at the thoracic-xiphoid level, which will measure the inspiratory and expiration mobility values and then be subtracted (Insp-Exp).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of abdominal level expandability.', 'description': 'In order to analyze abdominal expansibility, a tape measure will be used, placed at the level of the umbilical scar, which will measure the inspiratory and expiration mobility values and will be subtracted (Insp-Exp).', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in analysis of change in Infrared Thermography.', 'description': 'By means of an infrared thermographic camera, the blood circulation of the lower limbs will be evaluated by the temperature difference.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in aariation of blood lactate level.', 'description': "The blood lactate level will be measured by a lactometer, which will be collected from the volunteer's blood sample before starting the aerobic training on the treadmill and after training.", 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in 6-Minute Walk Test (Adapted)', 'description': 'The 6-minute-walk test will be adapted for neurological patients, which will be evaluated for exercise tolerance using a treadmill (Moviment RT200®). Volunteers will be assisted by the BrainMov® Rehabilitation and Physical Activity Station to stabilize the trunk and thus remain upright to wander on the treadmill', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in Mini-Mental State Examination (MINI MENTAL).', 'description': 'To evaluate the cognitive functions, the MINI MENTAL test will be applied.', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 weeks.'}
- {'measure': 'Change in Short Form 36 questionnaire (SF-36)', 'description': 'To evaluate the domains of quality of life: Functional Capacity, physical aspect, pain, general health, vitality, social aspect, emotional spectrum and mental health', 'timeFrame': 'Baseline (before starting rehabilitation) and after 9 week.'}

Please estimate the sample size based on the assumption: 
Not explicitly stated in the provided paragraph.
2.4
        Groups e sample size
        The present trial will include 90 patients who will be divided randomly into 3 experimental groups:
        
          
            (1)
            Control group (CCR): (nâ=â30) These individuals will receive only cardiorespiratory rehabilitation; therefore, no PBM Therapy will be applied, either real or placebo.
          
          
            (2)
            Transcranial Photobiomodulation Group (CR-PBM): (nâ=â30) Individuals in this group will receive PBM Therapy followed by cardiorespiratory rehabilitation.
          
          
            (3)
            Placebo Group Photobiomodulation (CR-PlaceboPBM): (nâ=â30) Individuals in this group will receive placebo PBM Therapy; the device will not deliver therapeutic light. Subsequently, they will receive cardiorespiratory rehabilitation.
          
        
        All patients, after completing the trial, may receive PBM Therapy treatment. Thus, if there is any interest of a patient who did not receive the PBM Therapy during the trial, this will be provided after trial completion